

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
12 September 2003 (12.09.2003)

PCT

(10) International Publication Number
WO 03/074028 A1(51) International Patent Classification⁷: **A61K 9/14, 9/16**(21) International Application Number: **PCT/EP03/02204**(22) International Filing Date: **7 March 2003 (07.03.2003)**(25) Filing Language: **English**(26) Publication Language: **English**(30) Priority Data:
2002/0184 **7 March 2002 (07.03.2002) IE**(71) Applicant (for all designated States except US): **EURAND PHARMACEUTICALS LTD.** [IE/IE]; Harcourt Centre, Harcourt Street, Dublin 2 (IE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv)) for US only

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BRESCIANI, Massimo** [IT/IT]; Via delle Campanelle, 170, I-34149 Trieste (IT); **DOBETTI, Luca** [IT/IT]; Via Vaglieri, 9/3, I-34149 Trieste (IT); **KIRCHMAYER, Stefano** [IT/IT]; Via Girolamo Muzio, 7, I-34143 Trieste (IT).(74) Agent: **GERVASI, Gemma**; Notarbartolo & Gervasi S.p.A., Corso di Porta Vittoria, 9, I-20122 Milan (IT).(54) Title: **PROCESS FOR LOADING AND THERMODYNAMICALLY ACTIVATING DRUGS ON POLYMERS BY MEANS OF SUPERCRITICAL FLUIDS**

(57) Abstract: The present invention refers to a process of loading drugs in a thermodynamic activated form into polymers by means of supercritical fluids. The process includes a pre-treatment step of the cross-linked polymer with pure supercritical fluid to allow a higher degree and a more rapid kinetic of drug loading into cross-linked polymers and also a higher thermodynamic activation of the drugs.

Best Available Copy

WO 03/074028 A1

PROCESS FOR LOADING AND THERMODYNAMICALLY ACTIVATING DRUGS ON POLYMERS BY MEANS OF SUPERCRITICAL FLUIDS

Field of the invention

The present invention refers to a process by means of the supercritical fluids for
5 loading and thermodynamically activating drugs on inert polymers.

Prior art

The technology with supercritical fluids has been developed owing to the particular properties of these fluids for a safer use of them in pharmaceutical field compared to the use of organic solvents.

10 A supercritical fluid is a material above its temperature and pressure conditions; it exhibits interesting behaviour by combining the properties of conventional liquids and gases. Although their gas-like low viscosities lead to higher rates of flow and diffusion, their liquid-like densities permit higher solvent power. For a detailed description of supercritical fluids, reference can be made to e.g. *Kirk-Othmer*,
15 *Encyclopedia of Chemical Technology*, vol.23, p.452-453.

The use of supercritical fluids could be, in principle, a valid alternative to the use of solvents in pharmaceutical field. In fact, the supercritical fluids, which are gases in standard environmental conditions, are completely removed from the compounds at the end of the process.

20 The supercritical fluids are extendedly used to reduce the particle size of drugs and to produce solid particles having a narrow size distribution. This can also be made at mild operating conditions, avoiding the stresses given by other more common techniques (i.e. milling, micronisation). As an example, WO 97/14407 (I. B. Henriksen et al.) deals with the preparation of water-insoluble drugs having an
25 average size from 100 to 300 nm, obtained by dissolving them in a solution and then spraying the solution into supercritical fluid in presence of suitable surface modifiers.

In the last year, the technology with supercritical fluids has been used for loading organic molecules in polymers. M. L. Sand (US Patent 4,598,006) discloses a
30 method for impregnating thermoplastic polymers with additives such as fragrances, pest control agents and pharmaceutical compounds. F. Carli et al.

(WO 99/25322) describes the loading of cross-linked polymers with drugs dissolved in supercritical fluids.

Oral delivery of poorly soluble drug has become, in the last years, one of the most challenging problems for advanced pharmaceutical research. This in turn leads to formulations with high drug content which often must be delivered repeatedly to obtain and maintain therapeutic plasma levels.

A way to enhance the solubility of poorly soluble or insoluble drugs is to thermodynamically activate them by forming an amorphous phase and/or nanocrystalline structures from the original crystalline state. This results in drug solubilisation kinetic, having dissolution rate and supersaturation concentrations, that is much higher than that obtainable with differently formulated drug in crystalline state. As a consequence, a strong increase of the drug effects "in-vivo" is allowed by enhancing the bioavailability, reducing the onset of action (t_{max}) and decreasing the variability between subjects.

The process described in WO 99/25322 has then been applied to check the suitability of supercritical fluids for the thermodynamic activation of drugs in cross-linked polymers. Positive results in terms of drug activation have been obtained.

Now, we have surprisingly found that a pre-treatment of the cross-linked polymer with pure supercritical fluid allows a higher degree and a more rapid kinetic of drug loading into cross-linked polymers (shorter process time) when compared to a standard process without pre-treatment. Moreover, a higher thermodynamic activation of the drugs is also obtained by means of a pre-treatment step.

Summary of the invention

The present invention refers to a process of loading drugs in a thermodynamic activated form into polymers by means of supercritical fluids. The process includes a pre-treatment step of the cross-linked polymer with pure supercritical fluid to allow a higher degree and a more rapid kinetic of drug loading into cross-linked polymers and also a higher thermodynamic activation of the drugs.

Detailed description of the invention

Object of the present invention is a process to load drugs into cross-linked polymers by means of supercritical fluids. The process includes a pre-treatment step of a cross-linked polymer with a supercritical fluid; this process allows to

obtain a higher degree and a more rapid kinetic of drug loading into cross-linked polymers (shorter process time) and also a higher thermodynamic activation of the drugs.

5 The supercritical fluid used in the pre-treatment step is free from any drugs (hereinafter referred as "pure supercritical fluid"); the pure supercritical fluid as such can be produced by means known in the art, i.e. by compressing the fluid and passing it through a heat exchanger in order to bring it beyond those temperature and pressure values at which it forms a supercritical fluid. Non limiting examples of substances from which supercritical fluids can be obtained
10 are carbon dioxide, hydrocarbon (ethylene, propylene), chlorofluorocarbon, nitrous oxide; supercritical fluids can be used alone or as a mixture of more of them.

In the pre-treatment step, the pure supercritical fluid is pumped into a reactor containing the pure cross-linked polymer (i.e. the polymer not containing any drugs) and is maintained in supercritical conditions of temperature and pressure;
15 the contact time between pure supercritical fluid and pure polymer is preferably between 1 minutes and 6 hours, most preferably between 5 minutes and 4 hours. The thus pre-treated polymer can be discharged from the reactor (after removing the supercritical fluid) and preserved for later loading with a drug, or can be immediately loaded with the drug. In both cases, the drug-loading step can be
20 effected by contacting the polymer with an aliquot of supercritical fluid containing the drug dissolved therein (this solution can be formed e.g. by passing a supercritical fluid through an extractor containing the drug to be solubilised) and pumping this solution into the reactor containing the cross-linked polymer, maintained in suitable supercritical conditions of temperature and pressure. The
25 contact time of the supercritical fluid containing the solubilised drug with the polymer is preferably between 2 minutes and 48 hours, most preferably between 10 minutes and 12 hours.

The contact between polymer and fluid, for both pre-treatment and drug-loading step, can be carried out in static or dynamic conditions or in a combination of
30 them. In the static case, a predetermined volume of supercritical fluid, with (drug-loading step) or without (pre-treatment step) the solubilised drug, is introduced in a container and allowed to equilibrate in contact with the polymer. In the dynamic

process, the stream of supercritical fluid, generated by the pump at the outlet of the extractor, is passed through a column containing the polymer. The combined process, static plus dynamic, can be obtained, for example, by passing dynamically a volume of supercritical fluid without the solubilised drug, through a column, by stopping the stream, leaving the supercritical fluid in contact with polymer in static conditions, and then passing again the supercritical fluid with the solubilised drug through the column, and leaving the supercritical fluid in contact with polymer in static conditions.

During both pre-treatment and drug-loading steps, pressure and temperature are maintained controlled, preferably constant, so as to maintain the fluid inside the reactor in supercritical conditions: this can be done by suitably using heat exchangers, constant monitoring of the pressure, and releasing controlled amounts of supercritical fluid when fresh fluid is added into the reactor.

At the outlet of the reactor, the fluid stream is passed through an absorber suitable to remove from the stream any traces of the residual drug. The fluid stream is then brought back to the ambient conditions and drained or, if necessary, cooled, sent to a reflux receiver and recycled.

The addition of the drug-loaded supercritical fluid results with the polymer structure being filled with the a supercritical solution of the drug. After the drug-loading phase, the supercritical fluid is removed from the reactor, causing the dissolved drug to precipitate in microparticle form inside the cross-linked polymeric network; the removal of the supercritical fluid can be conveniently effected by decreasing the pressure (and/or increasing the temperature) inside the reactor, thereby allowing the fluid to evaporate in gaseous form; when the concentration of drug increases over the solubility value in the fluid, the drug starts precipitating into the polymeric network; the total removal of the fluid leaves a solid powder in the reactor consisting of the drug-loaded polymer.

Cross-linked polymers useful for the present invention are any polymers (hydrophilic, hydrophobic or amphiphilic), whose polymeric chains are cross-linked by interchain bonds: these bonds can be naturally present in the polymer as such, or can be added by performing ad-hoc cross-linking reactions: as known in the art, cross-linking can be obtained by polymerisation processes that produces

physically crosslinked polymers, or by a chemical reaction of linear polymers with crosslinking agents. Not exhaustive examples of cross-linked polymer useful for the present invention are: cross-linked polyvinylpyrrolidone, cross-linked cellulose derivatives such as sodium croscarmellose, starch and its derivatives such as sodium starch glycolate, cyclodextrins and their derivatives, cross-linked polystyrene and cross-linked acrylic polymers. Cross-linked polymers can be used alone or as a mixture of more of them.

The cross-linked polymer loaded with this process contains preferably from 0.5% to 70%, more preferably from 3% to 50%, by weight of the active drug to the final total mass (cross-linked polymer + loaded drug).

Any drugs which can be solubilised into the supercritical fluid can be used for the purpose of the present invention. Among the drugs which can be loaded and activated according to the process of the invention, not exhaustive examples are Cox-2 inhibitors, anti-inflammatory drugs such as nimesulide, piroxicam, naproxene, ketoprofen, ibuprofen and diacerhein, anti-fungal drugs such as griseofulvin, itraconazole, fluconazole, miconazole and ketoconazole, bronchodilators/anti-asthmatic drugs such as zafirlukast, salbutamol, beclomethasone, flunisolide, clenbuterol, salmeterol and budesonide, steroids such as estradiol, estriol, progesterone, megestrol acetate and medroxyprogesterone acetate, anti-hypertensive/anti-thrombotic/vasodilator drugs such as nifedipine, nicergoline, nicardipine, lisinopril, enalapril, nicorandil, celiprolol and verapamil, benzodiazepines such as temazepam, diazepam, lorazepam, fludiazepam, medazepam and oxazolam, anti-migraine drugs such as zolmitriptan and sumatriptan, anti-hyperlipoproteinemic drugs such as fenofibrate, lovastatin, atorvastatin, fluvastatin and simvastatin, anti-viral/anti-bacterial drugs such as tosylflouxacin, ciprofloxacin, ritonavir, saquinavir, nelfinavir, acyclovir and indinavir, immunodepressant drugs such as tacrolimus, rapamycin and didanosine, anti-histaminic drugs such as loratidine, anti-tumoral drugs such as etoposide, bicalutamide, tamoxifen, doclitaxel and paclitaxel, anti-psychotic drugs such as risperidone, anti-osteoporotic drugs such as raloxifene, anti-convulsant such as carbamazepine, analgesic/narcotic drugs such as oxycodone, hydrocodone,

morphine and butorpanol, muscle relaxant such as tinazadine, anti-convulsant drug such as phenytoin, anti-ulcerative drugs such as famotidine.

The present inventors have found that when a cross-linked polymer is treated with a supercritical fluid according to the pre-treatment described above, it can be loaded with much higher amounts of drug than in the case of the untreated polymer: it is believed that the pre-treatment with the supercritical fluid (not containing any drugs) operates a chemical-physical modification in the polymer network, making it more prone to capture the drug particles in a subsequent drug-loading process: this fact is confirmed in the experimental part, where it is shown that a drug loading process by means of supercritical fluids results in a significantly higher percentage of drug incorporation if, in place of a common cross-linked polymer, the cross-linked polymer pre-treated in accordance with the pre-treatment of the invention is used.

In accordance with the above findings, the present invention also embraces a method to increase the drug-loading capacity of a cross-linked polymer, characterised by treating said cross-linked polymer with a supercritical fluid not containing any drugs. A further consequent object of the invention is a modified cross-linked polymer, having an enhanced capacity to incorporate drugs, obtained by treating a cross-linked polymer with a supercritical fluid not containing any drugs, in the modalities hereabove described.

A further surprising finding is that the drug incorporated in the polymer according to the present process shows an increased amount in its highly bioavailable amorphous and nanocrystalline fractions. The increase in the amorphous/nanocrystalline fraction obtains an increased bioavailability of the drug, due to the much quicker solubility of these forms with respect to the crystalline one.

In accordance with the above findings, the invention also comprises a method to increase the amorphous/nanocrystalline fraction of a drug (or to reduce its crystalline fraction and thereby increasing its activation degree), characterised by: (a) pre-treating a cross-linked polymer with a supercritical fluid; (b) contacting said pre-treated polymer with a supercritical fluid containing the drug dissolved therein; (c) removing the supercritical fluid, which results in the drug being precipitated

inside the cross-linked polymer in an increased amorphous/nanocrystalline fraction.

The process of the invention allows for the first time to incorporate large amounts of drugs into cross-linked polymers while, at the same time increasing substantially the bioavailability of the incorporated drug. Consequently, new highly potent pharmaceutical compositions can be obtained, associating a high drug content with an enhanced bioavailability of the same. These pharmaceutical compositions are also within the scope of the present invention.

The invention is further illustrated with reference to the following non-limitative examples.

EXPERIMENTALS

The presence of amorphous, nanocrystalline or crystal phase can be detected by means of Differential Scanning Calorimetry (DSC). Compared to the sharp melting peak of the drug crystal, the nanocrystals present a broader peak with a markedly lower maximum of temperature (I. Colombo et al. *4th Int. Conf. Pharm. Technol.*, 1986; F. Carli et al. *Acta Pharm. Jugosl.* **38**, 361, 1988). The amorphous phase does not show any thermal event.

In the examples, the activation level is expressed as the fraction of crystalline form. It is determined by comparing the enthalpy relative to the melting of the crystals in the polymer ($\Delta H_{\text{melting}}$) to that of pure drug (ΔH_0). The $\Delta H_{\text{melting}}/\Delta H_0$ ratio, normalized in accordance with the drug assayed in the polymer, is then considered equal to the fraction of crystalline form. The higher the amount of crystals (higher crystallinity), the lower the thermodynamic activation level of the drug.

Example 1

Reference (1R)

5 g of cross-linked polyvinylpyrrolidone, placed in a cylindrical reactor of 50 cm length and 0.6 cm diameter, are contacted for 8 hours with a 450 mL/min stream of supercritical in carbon dioxide (CO_2) saturated with nimesulide. Temperature and pressure are 40°C and 130 bar, respectively.

Invention (1I)

5 g of cross-linked polyvinylpyrrolidone, placed in a cylindrical reactor of 50 cm length and 0.6 cm diameter, are pre-treated for 30 minutes with a 450 mL/min stream of supercritical in carbon dioxide (CO₂). The cross-linked polymer is then contacted for 6 hours with a 450 mL/min stream of supercritical in carbon dioxide (CO₂) saturated with nimesulide. Temperature and pressure of both pre-treatment and loading steps are 40°C and 130 bar, respectively.

The results, reported in Table 1, show a higher degree of drug loading, a shorter process time (even considering the pre-treatment step) and a higher activation level (lower crystallinity) in the example 1I of the invention compared to the reference 1R of prior art.

Table 1.

	Drug content (%)	T _{melting} (°C)	ΔH _{melting} (J/g)	Crystallinity (%)
Nimesulide	-	148.4	109.2	100
1R	8.2	147.9	1.5	17
1I	9.1	no peak	-	0

Example 2

Reference (2R)

5 g of cross-linked polyvinylpyrrolidone, placed in a cylindrical reactor of 50 cm length and 0.6 cm diameter, are contacted for 8 hours with a 450 mL/min stream of supercritical in carbon dioxide (CO₂) saturated with ibuprofen. Temperature and pressure are 40°C and 130 bar, respectively.

Invention (2I)

5 g of cross-linked polyvinylpyrrolidone, placed in a cylindrical reactor of 50 cm length and 0.6 cm diameter, are pre-treated for 30 minutes with a 450 mL/min stream of supercritical in carbon dioxide (CO₂). The cross-linked polymer is then contacted for 6 hours with a 450 mL/min stream of supercritical in carbon dioxide (CO₂) saturated with ibuprofen. Temperature and pressure of both pre-treatment and loading steps are 40°C and 130 bar, respectively.

The results, reported in Table 2, show a higher degree of drug loading, a shorter process time (even considering the pre-treatment step) and a higher activation

level (lower crystallinity) in the example 2I of the invention compared to the reference 2R of prior art.

Table 2.

	Drug content (%)	T _{melting} (°C)	ΔH _{melting} (J/g)	Crystallinity (%)
Ibuprofen	-	75.1	122.9	100
1R	10.5	74.4	4.4	34
1I	16.0	no peak	-	0

5 Example 3

Reference (3R)

5 g of cross-linked polyvinylpyrrolidone, placed in a cylindrical reactor of 50 cm length and 0.6 cm diameter, are contacted for 8 hours with a 450 mL/min stream of supercritical in ethylene saturated with ibuprofen. Temperature and pressure are 30°C and 120 bar, respectively.

Invention (3I)

5 g of cross-linked polyvinylpyrrolidone, placed in a cylindrical reactor of 50 cm length and 0.6 cm diameter, are pre-treated for 30 minutes with a 450 mL/min stream of supercritical in ethylene. The cross-linked polymer is then contacted for 6 hours with a 450 mL/min stream of supercritical in ethylene saturated with ibuprofen. Temperature and pressure of both pre-treatment and loading steps are 40°C and 130 bar, respectively.

The results, reported in Table 3, show a higher degree of drug loading, a shorter process time (even considering the pre-treatment step) and a higher activation level (lower crystallinity) in the example 3I of the invention compared to the reference 3R of prior art.

Table 3.

	Drug content (%)	T_{melting} (°C)	ΔH_{melting} (J/g)	Crystallinity (%)
Ibuprofen	-	75.1	122.9	100
1R	6.4	74.0	7.2	92
1I	7.9	74.2	2.3	24

CLAIMS

1. A process to load a drug into a cross-linked polymer, comprising the following steps:
 - a. pre-treating said cross-linked polymer with a supercritical fluid;
 - 5 b. contacting said pre-treated cross-linked polymer with a supercritical fluid containing the drug dissolved therein;
 - c. removing the supercritical fluid, thereby causing the drug to precipitate inside the cross-linked polymer.
- 10 2. Process according to claim 1, wherein in step a. , the cross-linked polymer is maintained in contact with the supercritical fluid for a time comprised between 1 minute and 6 hours.
3. Process according to claims 1-2, wherein in step a. , the cross-linked polymer is maintained in contact with the supercritical fluid for a time comprised between 5 minutes and 4 hours.
- 15 4. Process according to claims 1-3, wherein in step b. , the pre-treated cross-linked polymer is maintained in contact with the supercritical fluid for a time comprised between 2 minutes and 48 hours.
5. Process according to claims 1-4, wherein in step b. , the pre-treated cross-linked polymer is maintained in contact with the supercritical fluid for a time
20 comprised between 10 minutes and 12 hours.
6. Process according to claims 1-5, wherein the contact of the cross-linked polymer with the supercritical fluid is effected in static and/or dynamic conditions.
7. Process according to claims 1-6, wherein said supercritical fluid is chosen
25 among carbon dioxide, ethylene, propylene, chlorofluorocarbon, nitrous oxide, and mixtures thereof.
8. Process according to claims 1-7, wherein said cross-linked polymer is chosen among cross-linked polyvinylpyrrolidone, cross-linked cellulose derivatives, starch and its derivatives, cyclodextrins and their derivatives, cross-linked
30 polystyrene, cross-linked acrylic polymers, and mixtures thereof.

9. Process according to claims 1-8, further characterised in that the thus loaded drug is present in the cross-linked polymer in high amorphous and nanocrystalline fraction.
10. A method to increase the drug-loading capacity of a cross-linked polymer, consisting in treating said cross-linked polymer with a supercritical fluid not containing any drugs.
11. Method according to claim 10, wherein the cross-linked polymer is maintained in contact with the supercritical fluid for a time comprised between 1 minute and 6 hours.
12. Method according to claims 10-11, wherein the cross-linked polymer is maintained in contact with the supercritical fluid for a time comprised between 5 minutes and 4 hours.
13. Method according to claims 10-12, wherein the contact of the polymer with the supercritical fluid is effected in static and/or dynamic conditions.
14. Method according to claims 10-13, wherein the supercritical fluid is chosen among carbon dioxide, ethylene, propylene, chlorofluorocarbon, nitrous oxide, and mixtures thereof.
15. Method according to claims 10-14, wherein the cross-linked polymer is chosen among cross-linked polyvinylpyrrolidone, cross-linked cellulose derivatives, starch and its derivatives, cyclodextrins and their derivatives, cross-linked polystyrene, cross-linked acrylic polymers, and mixtures thereof.
16. Modified cross-linked polymer, having enhanced drug-loading properties, obtainable by treating a cross-linked polymer with a supercritical fluid not containing any drugs.
17. Modified cross-linked polymer according to claim 16, obtainable by treating the cross-linked polymer with the supercritical fluid for a time comprised between 1 minute and 6 hours.
18. Modified cross-linked polymer according to claims 16-17, obtainable by treating the cross-linked polymer with the supercritical fluid for a time comprised between 5 minutes and 4 hours.

19. Modified cross-linked polymer according to claims 16-18, wherein the supercritical fluid is chosen among carbon dioxide, ethylene, propylene, chlorofluorocarbon, nitrous oxide, and mixtures thereof.
20. Modified cross-linked polymer according to claims 16-19, wherein the cross-linked polymer to be modified is chosen among cross-linked polyvinylpyrrolidone, cross-linked cellulose derivatives, starch and its derivatives, cyclodextrins and their derivatives, cross-linked polystyrene, cross-linked acrylic polymers, and mixtures thereof.
21. Modified cross-linked polymer according to claims 16-20, loaded with a drug.
22. Pharmaceutical composition containing the modified cross-linked polymer described in claim 21.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 03/02204

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K9/14 A61K9/16

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, EPO-Internal, EMBASE, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4 695 621 A (ALLADA) 22 September 1987 (1987-09-22) claims 1-6	16-20
X	WO 00 69559 A (ONTARIO POWER GENERATION INC.) 23 November 2000 (2000-11-23) page 2, line 5 - line 30 page 7, line 4 - line 12	16-20
X	WO 01 68054 A (EURAND INTERNATIONAL S.P.A.) 20 September 2001 (2001-09-20) claims 1,2,8-13	21,22
Y	WO 99 25322 A (VECTORPHARMA) 27 May 1999 (1999-05-27) cited in the application the whole document	1-22
-/-		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

Date of the actual completion of the international search

12 May 2003

Date of mailing of the international search report

20/05/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Benz, K

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/02204

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 94 18264 A (MINNESOTA MINING AND MANUFACTURING COMPANY)	1-22
X	18 August 1994 (1994-08-18) page 3, line 31 -page 5, line 3 page 19, line 5 -page 20, line 4 page 38, line 14 -page 39, line 5 page 42, table 4, comparative example A	16-19, 21,22

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/02204

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 4695621	A	22-09-1987	NONE	
WO 0069559	A	23-11-2000	US 6248797 B1 AU 4739300 A WO 0069559 A1 CA 2348521 A1	19-06-2001 05-12-2000 23-11-2000 23-11-2000
WO 0168054	A	20-09-2001	IT MI20000560 A1 AU 4068201 A BR 0109312 A WO 0168054 A1 EP 1267836 A1	17-09-2001 24-09-2001 17-12-2002 20-09-2001 02-01-2003
WO 9925322	A	27-05-1999	IT 1296464 B1 AU 738748 B2 AU 2153199 A BR 9814656 A CA 2310423 A1 WO 9925322 A2 EP 1033977 A2 JP 2001522873 T NZ 505290 A	25-06-1999 27-09-2001 07-06-1999 03-10-2000 27-05-1999 27-05-1999 13-09-2000 20-11-2001 28-08-2002
WO 9418264	A	18-08-1994	US 5340614 A CA 2154359 A1 DE 69427121 D1 DE 69427121 T2 EP 0683804 A1 JP 3263080 B2 JP 8506612 T WO 9418264 A1 US 5508060 A	23-08-1994 18-08-1994 23-05-2001 27-09-2001 29-11-1995 04-03-2002 16-07-1996 18-08-1994 16-04-1996

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.